A feasibility study of lorazepam for anxiety in palliative care (LORAZEPAM Study)

Demographic data for 15 adult patients with advanced cancer or advanced life-limiting disease and persistent or recurrent anxiety causing clinically significant distress or functional impairment at time of enrolment. 11 patients randomised to regular lorazepam treatment arm, 4 randomised to placebo, and treated for up to 12 weeks. Data collected at baseline, week 1,2,4,8,12 and follow-up at week 16 unless early discontinuation. Data includes anxiety measures (HADS-A, PROMIS 7a short form, PGIC), functional status (AKPS), other symptoms (ESAS), health-related quality of life (EQ 5D 5L), sleepiness (ESS), other adverse events and feasibility outcome data (recruitment, retention, completion of assessments, survival, acceptability, burden).